Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. The company is headquartered in La Jolla, California and currently employs 156 full-time employees. The company went IPO on 2024-05-28. The firm utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
Follow-Up Questions
What is Inhibrx Biosciences Inc (INBX)'s P/E Ratio?
The P/E ratio of Inhibrx Biosciences Inc is 0.2988
Who is the CEO of Inhibrx Biosciences Inc?
Mr. Mark Lappe is the Chairman of the Board of Director of Inhibrx Biosciences Inc, joining the firm since 2010.
What is the price performance of INBX stock?
The current price of INBX is $56.11, it has decreased 2.05% in the last trading day.
What are the primary business themes or industries for Inhibrx Biosciences Inc?
Inhibrx Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Inhibrx Biosciences Inc market cap?
Inhibrx Biosciences Inc's current market cap is $813.0M
Is Inhibrx Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Inhibrx Biosciences Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
